Clinical Trial: Study of Incidence of Drug-induced Upper Gastrointestinal Bleeding
Study Status: Completed
Recruit Status: Completed
Study Type: Observational
Official Title: Study of Incidence of Drug-induced Upper Gastrointestinal Bleeding
Brief Summary: The purpose of this study is to determine and analyse the incidence, severity, risk factors and routine management of acute drug-induced upper gastrointestinal bleeding (UGIB) in the population of Russian patients
Detailed Summary:
Sponsor: AstraZeneca
Current Primary Outcome: Number and percentage of patients with drug-induced upper gastrointestinal bleeding [ Time Frame: About 1 year ]
Original Primary Outcome: Same as current
Current Secondary Outcome:
- Number and percentage of patients with each symptom and each Forrest class of upper gastrointestinal bleeding [ Time Frame: About 1 year ]
- Number and percentage of patients with concomitant diseases contributing to drug-induced upper gastrointestinal bleeding and those who receive NSAIDs, antiplatelet agents, anticoagulants, steroids or combination therapy [ Time Frame: About 1 year ]
- Number and percentage of patients with each type of bleeding outcomes who received different types of hemostatic therapy [ Time Frame: About 1 year ]
Original Secondary Outcome: Same as current
Information By: AstraZeneca
Dates:
Date Received: June 25, 2010
Date Started: June 2010
Date Completion:
Last Updated: November 7, 2011
Last Verified: November 2011
